Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year’s literature

2012 ◽  
Vol 269 (10) ◽  
pp. 2157-2167 ◽  
Author(s):  
T. Kurzweg ◽  
N. Möckelmann ◽  
S. Laban ◽  
R. Knecht
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Options ◽  
Current Treatment

scholarly journals Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions

2018 ◽  
Author(s):  
Uta Rothschild ◽  
Laurent Muller ◽  
Axel Lechner ◽  
Hans A Schlsser ◽  
Dirk Beutner ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Options ◽  
Current Treatment ◽  
Future Directions ◽  
Scientific Rationale

Current Treatment Options for Metastatic Head and Neck Cancer

2012 ◽  
Vol 13 (1) ◽  
pp. 35-46 ◽  
Author(s):  
Katharine A. R. Price ◽  
Ezra E. Cohen
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Options ◽  
Current Treatment

scholarly journals Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

2018 ◽  
Vol 11 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Katjana S. Schwab ◽  
Glenn Kristiansen ◽  
Hans H. Schild ◽  
Stefanie E.A. Held ◽  
Annkristin Heine ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Treatment Options ◽  
Cell Cancer ◽  
Metastatic Malignant Melanoma ◽  
Programmed Death ◽  
The Us ◽  
Platinum Refractory

Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have been no data concerning the combination of nivolumab and ipilimumab in squamous cell head and neck cancer. We here present the case of a 46-year-old male with refractory squamous cell head and neck cancer, who was successfully treated with the PD-1 inhibitor nivolumab in combination with the anti-CTLA4 antibody ipilimumab.

QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17519-e17519
Author(s):  
Sachin Dhumal ◽  
Vijay Maruti Patil ◽  
Vanita Noronha ◽  
Amit Joshi ◽  
Atanu Bhattacharjee ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Head And Neck Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Treatment Options ◽  
Life Assessment ◽  
The Mean

e17519 Background: NACT (neoadjuvant chemotherapy) is one of the treatment options in advanced head and neck cancer (H&N cancer); however there is limited quality of life data available in these patients. Methods: Between August 2013- April 2014, 90 technically unresectable H&N cancer patients who were underwent NACT at our centre were selected for this analysis. EORTC QLQ-C30 and HN35 version 3.0 was used for quality of life assessment at baseline and after 02 cycles of NACT. PFS and OS was estimated by Kaplan Meier method. The mean change in QOL at various domains was calculated with 95% CI. The relationship between change in QOL domain and OS was analysed. Results: The median age of the cohort was 45 years (Range 21-65 years). The predominant subsite was oral cavity, in 62 patients (68.9%).The median PFS and OS was 10.53 months (95%CI 8.1-13.0) and 20.8 months (95%CI 15.1-26.5). The mean scores for all domains of QOL are shown in table 1. Conclusions: NACT leads to improvement in QOL in patients treated with head and neck cancers and its has impact on OS.[Table: see text]

Novel Treatment Options in Head and Neck Cancer

2017 ◽  
Vol 40 (6) ◽  
pp. 342-346 ◽  
Author(s):  
Patrick J. Schuler ◽  
Simon Laban ◽  
Johannes Doescher ◽  
Lars Bullinger ◽  
Thomas K. Hoffmann
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Options ◽  
Novel Treatment

scholarly journals Financial Toxicity in Head and Neck Cancer Patients Treated With Proton Therapy

2021 ◽  
Vol 8 (1) ◽  
pp. 366-373
Author(s):  
Grace L. Smith ◽  
Ya-Chen Tina Shih ◽  
Steven J. Frank
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Proton Therapy ◽  
Care Delivery ◽  
Treatment Options ◽  
Insurance Coverage ◽  
Financial Toxicity ◽  
Economic Implications

Abstract Cancer-related financial toxicity impacts head and neck cancer patients and survivors. With increasing use of proton therapy as a curative treatment for head and neck cancer, the multifaceted financial and economic implications of proton therapy—dimensions of “financial toxicity”—need to be addressed. Herein, we identify knowledge gaps and potential solutions related to the problem of financial toxicity. To date, while cost-effectiveness analysis has been used to assess the value of proton therapy for head and neck cancer, it may not fully incorporate empiric comparisons of patients' and survivors' lost productivity and disability after treatment. A cost-of-illness framework for evaluation could address this gap, thereby more comprehensively identifying the value of proton therapy and distinctly incorporating a measurable aspect of financial toxicity in evaluation. Overall, financial toxicity burdens remain understudied in head and neck cancer patients from a patient-centered perspective. Systematic, validated, and accurate measurement of financial toxicity in patients receiving proton therapy is needed, especially relative to conventional photon-based strategies. This will enrich the evidence base for optimal selection and rationale for payer coverage of available treatment options for head and neck cancer patients. In the setting of cancer care delivery, a combination of conducting proactive screening for financial toxicity in patients selected for proton therapy, initiating early financial navigation in vulnerable patients, engaging stakeholders, improving oncology provider team cost communication, expanding policies to promote price transparency, and expanding insurance coverage for proton therapy are critical practices to mitigate financial toxicity in head and neck cancer patients.

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Oncology ◽  
2014 ◽  
Vol 86 (4) ◽  
pp. 212-229 ◽  
Author(s):  
Nerina Denaro ◽  
Elvio Grazioso Russi ◽  
Vincenzo Adamo ◽  
Marco Carlo Merlano
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
State Of The Art ◽  
Treatment Options
Sign in / Sign up

Export Citation Format

Share Document